vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Grand Canyon Education, Inc. (LOPE). Click either name above to swap in a different company.
Grand Canyon Education, Inc. is the larger business by last-quarter revenue ($308.1M vs $168.4M, roughly 1.8× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 5.3%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 5.9%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Grand Canyon Education, Inc. (GCE) is an American for-profit corporation that provides services to universities, specializing in program development, online education, and operational support. Formerly affiliated with Grand Canyon University (GCU), a Christian university in Arizona, GCE became a separate publicly traded company in 2008.
ESPR vs LOPE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $308.1M |
| Net Profit | — | $86.7M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 35.1% |
| Net Margin | — | 28.1% |
| Revenue YoY | 143.7% | 5.3% |
| Net Profit YoY | — | 5.9% |
| EPS (diluted) | $0.32 | $3.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $308.1M | ||
| Q3 25 | $87.3M | $261.1M | ||
| Q2 25 | $82.4M | $247.5M | ||
| Q1 25 | $65.0M | $289.3M | ||
| Q4 24 | $69.1M | $292.6M | ||
| Q3 24 | $51.6M | $238.3M | ||
| Q2 24 | $73.8M | $227.5M | ||
| Q1 24 | $137.7M | $274.7M |
| Q4 25 | — | $86.7M | ||
| Q3 25 | $-31.3M | $16.3M | ||
| Q2 25 | $-12.7M | $41.5M | ||
| Q1 25 | $-40.5M | $71.6M | ||
| Q4 24 | — | $81.9M | ||
| Q3 24 | $-29.5M | $41.5M | ||
| Q2 24 | $-61.9M | $34.9M | ||
| Q1 24 | $61.0M | $68.0M |
| Q4 25 | 50.6% | 35.1% | ||
| Q3 25 | -11.4% | 6.9% | ||
| Q2 25 | 8.6% | 20.9% | ||
| Q1 25 | -34.0% | 30.4% | ||
| Q4 24 | -6.4% | 34.2% | ||
| Q3 24 | -31.0% | 20.2% | ||
| Q2 24 | 3.5% | 18.8% | ||
| Q1 24 | 52.5% | 30.8% |
| Q4 25 | — | 28.1% | ||
| Q3 25 | -35.9% | 6.2% | ||
| Q2 25 | -15.4% | 16.8% | ||
| Q1 25 | -62.2% | 24.8% | ||
| Q4 24 | — | 28.0% | ||
| Q3 24 | -57.2% | 17.4% | ||
| Q2 24 | -83.9% | 15.3% | ||
| Q1 24 | 44.3% | 24.8% |
| Q4 25 | $0.32 | $3.13 | ||
| Q3 25 | $-0.16 | $0.58 | ||
| Q2 25 | $-0.06 | $1.48 | ||
| Q1 25 | $-0.21 | $2.52 | ||
| Q4 24 | $-0.14 | $2.83 | ||
| Q3 24 | $-0.15 | $1.42 | ||
| Q2 24 | $-0.33 | $1.19 | ||
| Q1 24 | $0.34 | $2.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $111.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $746.9M |
| Total Assets | $465.9M | $992.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $111.8M | ||
| Q3 25 | $92.4M | $97.3M | ||
| Q2 25 | $86.1M | $192.3M | ||
| Q1 25 | $114.6M | $144.5M | ||
| Q4 24 | $144.8M | $324.6M | ||
| Q3 24 | $144.7M | $263.6M | ||
| Q2 24 | $189.3M | $241.3M | ||
| Q1 24 | $226.6M | $196.2M |
| Q4 25 | $-302.0M | $746.9M | ||
| Q3 25 | $-451.4M | $758.0M | ||
| Q2 25 | $-433.5M | $778.0M | ||
| Q1 25 | $-426.2M | $780.7M | ||
| Q4 24 | $-388.7M | $783.9M | ||
| Q3 24 | $-370.2M | $764.1M | ||
| Q2 24 | $-344.2M | $759.2M | ||
| Q1 24 | $-294.3M | $759.4M |
| Q4 25 | $465.9M | $992.3M | ||
| Q3 25 | $364.0M | $1.0B | ||
| Q2 25 | $347.1M | $1.0B | ||
| Q1 25 | $324.0M | $1.0B | ||
| Q4 24 | $343.8M | $1.0B | ||
| Q3 24 | $314.1M | $992.9M | ||
| Q2 24 | $352.3M | $992.7M | ||
| Q1 24 | $373.1M | $1.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $130.5M |
| Free Cash FlowOCF − Capex | — | $122.9M |
| FCF MarginFCF / Revenue | — | 39.9% |
| Capex IntensityCapex / Revenue | 0.0% | 2.5% |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | $238.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $130.5M | ||
| Q3 25 | $-4.3M | $-48.6M | ||
| Q2 25 | $-31.4M | $124.0M | ||
| Q1 25 | $-22.6M | $67.6M | ||
| Q4 24 | $-35.0M | $135.8M | ||
| Q3 24 | $-35.3M | $-29.4M | ||
| Q2 24 | $-7.2M | $98.6M | ||
| Q1 24 | $53.8M | $85.0M |
| Q4 25 | — | $122.9M | ||
| Q3 25 | — | $-58.3M | ||
| Q2 25 | — | $115.4M | ||
| Q1 25 | — | $58.7M | ||
| Q4 24 | — | $126.1M | ||
| Q3 24 | $-35.5M | $-39.0M | ||
| Q2 24 | $-7.3M | $89.6M | ||
| Q1 24 | $53.8M | $76.0M |
| Q4 25 | — | 39.9% | ||
| Q3 25 | — | -22.3% | ||
| Q2 25 | — | 46.6% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | — | 43.1% | ||
| Q3 24 | -68.7% | -16.3% | ||
| Q2 24 | -9.9% | 39.4% | ||
| Q1 24 | 39.0% | 27.7% |
| Q4 25 | 0.0% | 2.5% | ||
| Q3 25 | 0.0% | 3.7% | ||
| Q2 25 | 0.0% | 3.5% | ||
| Q1 25 | 0.0% | 3.1% | ||
| Q4 24 | 0.0% | 3.3% | ||
| Q3 24 | 0.3% | 4.0% | ||
| Q2 24 | 0.1% | 3.9% | ||
| Q1 24 | 0.1% | 3.3% |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | -2.99× | ||
| Q2 25 | — | 2.98× | ||
| Q1 25 | — | 0.94× | ||
| Q4 24 | — | 1.66× | ||
| Q3 24 | — | -0.71× | ||
| Q2 24 | — | 2.83× | ||
| Q1 24 | 0.88× | 1.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
LOPE
Segment breakdown not available.
